On the basis of identified correlations between KLK6 and CSF AD biomarkers, we further conclude that although CSF KLK6 levels are not useful as a biomarker for AD per se, they are related to AD neuropathological processes, and that this association may change over time as disease progresses. The gene discussed is KLK6; the disease is Alzheimer disease.